Respiratory syncytial virus: Different criteria for palivizumab use in different areas?

Southern Medical Journal

Volumn 100, Issue 7, 2007, Pages 661-662

  Mitchell, Ian ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; PALIVIZUMAB;

DRUG EFFICACY; EDITORIAL; HUMAN; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TREATMENT DURATION; TREATMENT PLANNING; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION, PASSIVE; INFANT; PRACTICE GUIDELINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SEASONS;

EID: 34447295352     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318070ca99     Document Type: Editorial

References (5)

1. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003;22(2 Suppl):S21-32.
2. Weber MW, Mulholland EK, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 1998; 3:268-280.
3. Chavez-Bueno S, Mejias A, Welliver RC. Respiratory syncytial virus bronchiolitis: current and future strategies for treatment and prophylaxis. Treat Respir Med 2006;5:483-494.
4. Bauman J, Eggleston M, Oquist N, et al. Respiratory syncytial virus: seasonal data from regions of Florida and implications for palivizumab. South Med J 2007;100:669-676.
5. Available at: http://doh.state.fl.us/disease_ctrl/epi/RSV/rsv.htm. Accessed on February 26, 2007.